A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III ( APOC3 ) and, as a result, express half the amount of apoC-III present in noncarriers. Mutation carriers compared with noncarriers had lower fasting and postprandial serum triglycerides, higher levels of HDL-cholesterol and lower levels of LDL-cholesterol. Subclinical atherosclerosis, as measured by coronary artery calcification, was less common in carriers than noncarriers, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function variants of APOC3 that result in reduced synthesis of the protein are associated with absent or low circulating apoCIII levels, increased efficiency of TG removal from TRL, and lower plasma TG levels,59,60”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, rare heterozygous LOF variants in APOC3 encoding apo C-III are associated with ∼50% reduced TG levels and significantly increased clearance of very-low-density lipoprotein (VLDL).8,9”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Founder populations (such as those from Finland and Iceland) have provided multiple examples of otherwise rare risk alleles driven to higher frequency locally through drift and/or selection49–52.”
From A brief history of human disease genetics (2020) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Cited by
Items 201–300 of 682
Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels
Lu, W., Cheng, Y.-C., Chen, K., Wang, H., Gerhard, G. S., Still, C. D., Chu, X., Yang, R., Parihar, A., O'Connell, J. R., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu731 · Cited by 52
“The APOC3 R19X is a null allele that reduces apoC-III production in heterozygotes by 50% and is associated with reduced triglycerides and increased HDL-C, LDL-C and cardioprotection as measured by less coronary calcification (31) and a lower rate of myocardial infarction (32,33).”
BackgroundSelf-citationApolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL
Larsson, M., Allan, C. M., Jung, R. S., Heizer, P. J., Beigneux, A. P., Young, S. G., & Fong, L. G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m078220 · Cited by 53
The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
Luo, M., & Peng, D. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0352-y · Cited by 50
“The negative effects of apoCIII agree with gene analysis in which null mutation or missense mutation of apoCIII produces apoCIII deficiency and confers lifelong cardioprotection [4, 5, 11, 12].”
BackgroundTriglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 60
“Metaanalyses provide supportive evidence for the association between elevated triglyceride levels and CV disease (CVD) risk (14,15).”
InfluentialDunbar, R. L., Nicholls, S. J., Maki, K. C., Roth, E. M., Orloff, D. G., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0100-8 · Cited by 52
“Moreover, loss-of-function polymorphisms in the Apo CIII gene (APOC3) have been associated with lower TG and reduced coronary and ischemic vascular disease risks [13–15].”
BackgroundHuman genetics of HDL: Insight into particle metabolism and function
Brunham, L. R., & Hayden, M. R. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.01.001 · Cited by 53
ApoCIII: A multifaceted protein in cardiometabolic disease
D'Erasmo, L., Di Costanzo, A., Gallo, A., Bruckert, E., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 50
Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025098 · Cited by 55
“In a striking example of validation, carriers of a different APOC3 genotype in a homogenous Pennsylvania Amish population also showed low APOC-3 levels, a favorable lipid phenotype, better arterial health score, and enhanced longevity (Pollin et al. 2008).”
Karwatowska-Prokopczuk, E., Tardif, J.-C., Gaudet, D., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Amour, E. S., Alexander, V. J., Xia, S., et al. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.06.005 · Cited by 51
Shah, T., Zabaneh, D., Gaunt, T., Swerdlow, D. I., Shah, S., Talmud, P. J., Day, I. N., Whittaker, J., Holmes, M. V., Sofat, R., et al. (2013) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.112.964254 · Cited by 52
The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis
Gordts, P. L. S. M., & Esko, J. D. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.05.010 · Cited by 54
Basu, D., & Bornfeldt, K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00504 · Cited by 52
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Wei, J., Ouyang, H., Wang, Y., Pang, D., Cong, N. X., Wang, T., Leng, B., Li, D., Li, X., Wu, R., et al. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08401.x · Cited by 50
Amar, M. J., Sakurai, T., Sakurai-Ikuta, A., Sviridov, D. O., Freeman, L. A., Ahsan, L., & Remaley, A. T. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220418 · Cited by 57
“plasma levels of triglycerides have been associated with a markedly lower cardiovascular disease risk (Pollin et al., 2008).”
BackgroundZheng, C. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000040 · Cited by 50
“Heterozygouscarriersof thismutationhavea favorable blood lipid profile with low plasma triglyceride, low LDL cholesterol and high HDL cholesterol, suggesting lifelong deficiency of apoCIII is cardioprotective [12].”
BackgroundDistribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population
Lim, E. T., Würtz, P., Havulinna, A. S., Palta, P., Tukiainen, T., Rehnström, K., Esko, T., Mägi, R., Inouye, M., Lappalainen, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004494 · Cited by 49
“5–5%) variants in complex diseases and traits such as triglycerides [1], insulin processing [2], bone mineral density [3], Alzheimer’s disease [4], impulsivity [5], and prostate cancer [6], some of which confer protection from disease [4].”
BackgroundThe genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
Chew, N., Chong, B., Ng, C. H., Kong, G., Chin, Y. H., Xiao, W., Lee, C. J. M., Dan, Y. Y., Muthiah, M. D., & Foo, R. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.971484 · Cited by 53
“5% of heterozygous carriers of the null gene APOC3 mutation express half the amount of APOC3 in noncarriers.”
BackgroundInfluentialPovel, C. M., Boer, J. M. A., Onland‐Moret, N. C., Dollé, M. E. T., Feskens, E. J. M., & van der Schouw, Y. T. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-133 · Cited by 58
“LPL – rs326 [49] APOA1 – rs2075292 [49] APOA1, APOC3, APOA4, APOA5 – rs10892151 [50] APOA1, APOC3, APOA4, APOA5 – rs4938303[21] CLIP2 – rs7557067 [26]”
Nanoparticles and siRNA: a new era in therapeutics?
Pérez-Carrión, M. D., Posadas, I., & Ceña, V. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107102 · Cited by 48
Docosahexaenoic acid suppresses the expression of FoxO and its target genes
Chen, Y.-J., Chen, C.-C., Li, T., Wang, P.-H., Liu, L.-R., Chang, F.-Y., Wang, Y.-C., Yu, Y., Lin, S., Mersmann, H. J., et al. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.11.003 · Cited by 52
“In line with these results, the null mutation of human subject with half expression of apoC-III has a profound effect on lowering the fasting and postprandial serum triacylglycerol and low-density lipoprotein cholesterol and elevating the levels of high-density lipoprotein cholesterol [38].”
ResultMendelian Disorders of High-Density Lipoprotein Metabolism
Oldoni, F., Sinke, R. J., & Kuivenhoven, J. A. (2014) · Circulation Research · doi:10.1161/circresaha.113.300634 · Cited by 49
“3) associated with apparent cardioprotection.(43) Overexpression of human apoC-III in mice results in hypertriglyceridemia,(227) whereas”
BackgroundRaising HDL cholesterol in women
Merchant, N. (2009) · International Journal of Women s Health · doi:10.2147/ijwh.s5110 · Cited by 57
A genome-wide association study of tick burden and milk composition in cattle
Turner, L. B., Harrison, B. E., Bunch, R. J., Porto-Neto, L. R., Li, Y., & Barendse, W. (2010) · Animal Production Science · doi:10.1071/an09135 · Cited by 54
“2008), as well as either discovering, or rediscovering, QTL or RACT of moderate to large effect in humans (Todd et al. 1987; Ellis et al. 2001; Burton et al. 2007; Gieger et al. 2008; Hillmer et al. 2008; Pollin et al. 2008; Benyamin et al. 2009; Daly et al. 2009).”
BackgroundApolipoprotein C3: form begets function
Bornfeldt, K. E. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100475 · Cited by 45
“In the above study (4), remnant cholesterol was estimated by subtracting LDL-cholesterol and HDL-cholesterol from total cholesterol, and in a subcohort was measured directly.”
BackgroundInfluentialBallantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.008 · Cited by 47
Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis
Natarajan, P., Kohli, P., Baber, U., Nguyen, K.-D. H., Sartori, S., Reilly, D. F., Mehran, R., Muntendam, P., Fuster, V., Rader, D. J., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.866 · Cited by 47
Sahebkar, A., Simental-Mendía, L. E., Mikhailidis, D. P., Pirro, M., Banach, M., Sirtori, C. R., & Reiner, Ž. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1511919 · Cited by 48
Lee, W.-J., Pollin, T. I., O’Connell, J. R., Agarwala, R., & Schäffer, A. A. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-68 · Cited by 50
“…influencing traits such as cardiac repolarization [17], type 2 diabetes [18], hypertension [19], and fasting and post-prandial triglyceride levels [20] or to validate locus associations first discovered in other populations, e.g., diabetes [21], human height [22], fasting glucose levels [23],…”
BackgroundInfluentialSelf-citationvan Beek, J. H. D. A., de Moor, M. H. M., Geels, L. M., Sinke, M. R. T., de Geus, E. J. C., Lubke, G. H., Kluft, C., Neuteboom, J., Vink, J. M., Willemsen, G. A. H. M., et al. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.09.016 · Cited by 50
APOC3, Coronary Disease, and Complexities of Mendelian Randomization
Cohen, J. C., Stender, S., & Hobbs, H. H. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.007 · Cited by 46
“The effects of APOC3 inactivation on LDL-C levels remain inconclusive (Pollin et al., 2008; Tachmazidou et al., 2013).”
BackgroundSun, H.-Y., Lin, C., Lee, J., Wang, S.-W., Cheng, P., Wu, I., Chang, T., Lai, M., Shieh, D., & Young, K.-C. (2012) · Gut · doi:10.1136/gutjnl-2011-301798 · Cited by 47
Severe hypertriglyceridemia: Existing and emerging therapies
Malick, W. A., Do, R., & Rosenson, R. S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108544 · Cited by 40
Phenotypes and Genotypes of High Density Lipoprotein Cholesterol in Exceptional Longevity
Milman, S., Atzmon, G., Crandall, J. P., & Barzilai, N. (2013) · Current Vascular Pharmacology · doi:10.2174/1570161111666131219101551 · Cited by 49
“In a cohort of the Lancaster Amish, a null mutation in APOC-3 (R19X), which results in lower APOC-3 levels, was associated with higher HDL levels and lower prevalence of subclinical atherosclerosis[29], further suggesting a protective role of genotypes linked to diminished APOC-3.”
BackgroundThematic Series on the Pathobiology of Vascular Calcification
Towler, D. A., & Demer, L. L. (2011) · Circulation Research · doi:10.1161/circresaha.110.234419 · Cited by 44
The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 53
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 46
Dai, W., Zhang, Z., Yao, C., & Zhao, S. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1166-5 · Cited by 47
“reduction of circulating apoC3 levels [5].”
The Complex Genetic Basis of Plasma Triglycerides
Johansen, C. T., & Hegele, R. A. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0243-2 · Cited by 46
Mining the genome for lipid genes
Kuivenhoven, J. A., & Hegele, R. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.028 · Cited by 52
“religious isolate 107720 [151] Mutation carriers comparedwith non-carriers also had lower fasting and postprandial TG, higher”
BackgroundBotteri, G., Montori-Grau, M., Gumà, A., Pizarro‐Delgado, J., Cedó, L., Escolá‐Gil, J. C., Li, D., Barroso, E., Palomer, X., Kohan, A. B., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4401-5 · Cited by 44
“In agreement with this, antisense-mediated lowering of plasma apoCIII improves dyslipidaemia and insulin sensitivity in humans with type 2 diabetes [39] and a null mutation in human APOCIII confers a favourable plasma lipid profile, although it does not improve insulin sensitivity [8].”
Novel Therapeutic Targets for Managing Dyslipidemia
Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 44
Emdin, C. A., Khera, A. V., Aragam, K., Haas, M., Chaffin, M., Klarin, D., Natarajan, P., Bick, A., Zekavat, S. M., Nomura, A., et al. (2019) · Diabetes · doi:10.2337/db18-0857 · Cited by 42
Implementation of public health genomics in Pakistan
Riaz, M., Tiller, J. M., Ajmal, M., Azam, M., Qamar, R., & Lacaze, P. A. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0428-z · Cited by 49
A new, powerful player in lipoprotein metabolism: brown adipose tissue
Bartelt, A., Merkel, M., & Heeren, J. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0858-3 · Cited by 52
Olkkonen, V. M., Sinisalo, J. P., & Jauhiainen, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.019 · Cited by 43
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40
“Background There is a growing body of recently published genetic and epidemiological evidences which demonstrated a causal role of triglycerides (TG) and TG-rich lipoproteins in the pathogenesis of atherosclerosis and particularly coronary artery disease (CAD) [1–5].”
BackgroundBashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Proteomic Analysis of Proteins Eliminated by Low‐Density Lipoprotein Apheresis
Yuasa, Y., Osaki, T., Makino, H., Iwamoto, N., Kishimoto, I., Usami, M., Minamino, N., & Harada‐Shiba, M. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12056 · Cited by 40
“Null mutation in Apo C-III confers favorable lipid profiles and apparent cardioprotection without any obvious detrimental effect; this raised the possibility that therapies targeting Apo C-III would be clinically effective in reducing cardiovascular events (26).”
BackgroundShin, M., & Krauss, R. M. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.025 · Cited by 42
The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.003 · Cited by 42
“In the first study, Crawford et al. [26] examined 1113 Amish participants of the Epidemiologic Architecture for Genes Linked to Environment Study and found that individuals carrying a LOF mutation in APOC3 had about half the triglyceride levels and more than 20% higher HDL-C levels compared to non-carriers.”
InfluentialSundaram, M., Curtis, K. R., Amir Alipour, M., LeBlond, N. D., Margison, K. D., Yaworski, R. A., Parks, R. J., McIntyre, A. D., Hegele, R. A., Fullerton, M. D., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m077313 · Cited by 38
“Three loss-of-function variants, namely, Lys58Glu (11), Ala23Thr (10), and Arg19X (21), are associated with a hypotriglyceridemia phenotype and may confer cardioprotective effect.”
BackgroundTargeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 43
“After the discovery of ANGPTL3 [69], genetic studies showed that loss-of-function mutations of ANGPTL3 resulted in a hypobetalipoproteinemia associated with decreased plasma TG, HDL-C and LDL-C levels [70].”
BackgroundInfluentialApolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits
Yan, H., Niimi, M., Matsuhisa, F., Zhou, H., Kitajima, S., Chen, Y., Wang, C., Yang, X., Yao, J. Q., Yang, D., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314368 · Cited by 43
Hussain, A., Sun, C., Selvin, E., Nambi, V., Coresh, J., Jia, X., Ballantyne, C. M., & Hoogeveen, R. C. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa152 · Cited by 43
“We studied two proteins involved in TG metabolism, ANGPTL3 and apoC-III, as these are targets of novel therapies currently in clinical trials(38) and polymorphisms in ANGPTL3 and APOC3 are associated with ASCVD risk.(13,17,39) We found positive significant associations of apoC-III with both RLP-C and LDL-TG and of ANG…”
BackgroundGoyal, S., Tanigawa, Y., Zhang, W., Chai, J. F., Almeida, M., Sim, X., Lerner, M. R., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01531-8 · Cited by 48
Wojczynski, M. K., Parnell, L. D., Pollin, T. I., Lai, C., Feitosa, M. F., O’Connell, J. R., Wood, A. C., Gibson, Q., Aslibekyan, S. W., Ryan, K. A., et al. (2015) · Metabolism · doi:10.1016/j.metabol.2015.07.001 · Cited by 41
“To date, there has been one genomewide association study (GWAS) of PPL in an extended pedigree which found a rare mutation [16], while the majority of genetic PPL studies have investigated candidate genes with known involvement in lipid metabolism (i.”
Self-citationAssociations of the APOC3 rs5128 polymorphism with plasma APOC3 and lipid levels: a meta-analysis
Song, Y., Zhu, L., Richa, M., Li, P., Yang, Y., & Li, S. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0027-0 · Cited by 45
“APOC3 also play important roles in modulating other lipid variables [9].”
BackgroundApolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
“Lower TG and LDL-C concentrations were observed in mutation carriers and the incidence of subclinical atherosclerosis was decreased, indicating a cardioprotective effect of apoCIII deficiency.(130) The same mutation has subsequently been found to be enriched in an isolated Greek population, in which it could be associ…”
BackgroundZuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 40
“Additionally, the discovery of LOF variants in APOC3 [31], encoding small apoCIII proteins that are associated with a low-risk lipid profile and fewer cardiovascular events [30,32], has emerged into trials with antisense oligonucleotides and are now approved in Europe for treating familial chylomicron syndrome patient…”
BackgroundInfluentialManaging Dyslipidemia in Type 2 Diabetes
Nelson, A. J., Rochelau, S. K., & Nicholls, S. J. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.004 · Cited by 39
Wang, X., Gong, Y., Deng, T., Zhang, L., Liao, X., Han, C., Yang, C., Huang, J., Wang, Q., Song, X., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29131 · Cited by 43
“Loss of function of mutations in rs147210663, rs76353203, and rs138326449 sites of APOC3 gene have been observed as being associated with favorable lipid profiles and lowered risks of cardiovascular diseases.(61,62) Variants with the largest effect sizes on cholesterol traits of APOB and APOE, APOA4, and APOA5 variant…”
BackgroundTanaka, H., Nagashima, T., Shimaya, A., Urano, Y., Shimokawa, T., & Shibasaki, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.07.018 · Cited by 38
Quartet of APOCs and the Different Roles They Play in Diabetes
Hsu, C.-C., Kanter, J. E., Kothari, V. M., & Bornfeldt, K. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318290 · Cited by 42
Reeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 36
“[24] were the first to show how a rare APOC3 null-mutation found in the Lancaster county Amish population (n1⁄41033) correlated with reduced triglycerides levels and CVD risk as measured by lower coronary calcium score in mutation-carriers.”
BackgroundSafety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
Atherosclerosis Calcification: Focus on Lipoproteins
Neels, J. G., Lefthériotis, G., & Chinetti, G. (2023) · Metabolites · doi:10.3390/metabo13030457 · Cited by 47
“Heterozygous carriers of a null mutation (R19X) in the gene encoding apoCIII, compared with noncarriers, had lower fasting and postprandial serum triglycerides, higher levels of HDL-cholesterol, lower levels of LDL-cholesterol and less coronary artery calcification [48,49].”
BackgroundNiu, T.-H., Jiang, M., Xin, Y.-N., Jiang, X.-J., Lin, Z.-H., & Xuan, S.-Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i13.3655 · Cited by 39
Functional validation of new pathways in lipoprotein metabolism identified by human genetics
Bauer, R. C., Stylianou, I. M., & Rader, D. J. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834469b3 · Cited by 36
Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
Malick, W. A., Waksman, O., Do, R., Koenig, W., Pradhan, A. D., Stroes, E. S. G., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.034 · Cited by 35
Ding, Y., Wang, Y., Zhu, H., Fan, J., Yu, L., Liu, C., & Liu, E. (2010) · Transgenic Research · doi:10.1007/s11248-010-9467-5 · Cited by 40
“Clinically, apoCIII has been recognized as an independent risk factor for cardiovascular disease ( Ooi et al. 2008 ).”
BackgroundVisceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content
Peter, A., Kantartzis, K., Machicao, F. E., Machann, J., Wagner, S., Templin, S., Königsrainer, I., Königsrainer, A., Schick, F., Fritsche, A., et al. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.154 · Cited by 42
APOC3 siRNA and ASO therapy for dyslipidemia
Chebli, J., Larouche, M., & Gaudet, D. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000857 · Cited by 35
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
“on subclinical atherosclerosis findings measured by calcium score [116].”
BackgroundOrho‐Melander, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12407 · Cited by 35
Godzień, J., Ciborowski, M., Armitage, E. G., Jorge, I., Camafeita, E., Burillo, E., Martı́n-Ventura, J. L., Rupérez, F. J., Vázquez, J., & Barbas, C. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00898 · Cited by 35
Li, M.-R., Zhang, S., Chao, K., Liao, X., Yao, J., Chen, M., & Zhong, B. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i38.14010 · Cited by 38
Targeting ApoC-III to Reduce Coronary Disease Risk
Khetarpal, S. A., Qamar, A., Millar, J. S., & Rader, D. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0609-y · Cited by 35
Crawford, D. C., Dumitrescu, L., Goodloe, R., Brown-Gentry, K., Boston, J., McClellan, B., Sutcliffe, C., Wiseman, R., Baker, P., Pericak-Vance, M. A., et al. (2014) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000369 · Cited by 35
“Midwestern US Amish Population The original discovery of APOC3 R19X involved Amish participants from Pennsylvania.(11) Given the migration patterns and history of the Amish in the Americans, we sought to estimate the prevalence of 19X in a non-Pennsylvania Amish population to determine if the cardio-protective variant…”
BackgroundResultInfluentialSelf-citationKegulian, N. C., Ramms, B., Horton, S. B., Trenchevska, O., Nedelkov, D., Graham, M. J., Lee, R. G., Esko, J. D., Yassine, H. N., & Gordts, P. L. S. M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312723 · Cited by 38
Aroner, S. A., Yang, M., Li, J., Furtado, J. D., Sacks, F. M., Tjønneland, A. M., Overvad, K., Cai, T., & Jensen, M. K. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx143 · Cited by 35
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 34
“calcium scores compared to non-carriers [29], findings that”
BackgroundLutsey, P. L., Rasmussen‐Torvik, L. J., Pankow, J. S., Alonso, Á., Smolenski, D. J., Tang, W., Coresh, J., Volcik, K. A., Ballantyne, C. M., Boerwinkle, E., et al. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.959619 · Cited by 38
Human Knockout Carriers: Dead, Diseased, Healthy, or Improved?
Narasimhan, V. M., Xue, Y., & Tyler‐Smith, C. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.006 · Cited by 39
“For example, in addition to the PCSK9 knockouts mentioned above, APOC3 knockouts have been assessed – APOC3 deficiency has been shown to lead to reduced triglyceride levels in humans [52].”
BackgroundShen, H., Damcott, C., Shuldiner, S. R., Chai, S., Yang, R., Hu, H., Gibson, Q., Ryan, K. A., Mitchell, B. D., & Gong, D. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2011.105 · Cited by 32
“Advances in genetic technology have enabled the identification of many of these rare mutations and has provided the opportunity to glean insights into mechanisms underlying both rare and common phenotypes, which would otherwise be difficult in the general population”
Self-citationHsueh, W.-C., Nair, A. K., Kobes, S., Chen, P., Göring, H. H. H., Pollin, T. I., Malhotra, A., Knowler, W. C., Baier, L. J., & Hanson, R. L. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001809 · Cited by 32
Self-citationImportance of Genetic Studies of Cardiometabolic Disease in Diverse Populations
Fernández‐Rhodes, L., Young, K. L., Lilly, A. G., Raffield, L. M., Highland, H. M., Wojcik, G. L., Agler, C. S., Love, S.-A. M., Okello, S., Petty, L. E., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.315893 · Cited by 39
Kristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 35
Genetic and functional evidence links a missense variant in B4GALT1 to lower LDL and fibrinogen
Montasser, M. E., Hout, C. V. V., Miloscio, L., Howard, A. D., Rosenberg, A., Callaway, M. B., Shen, B., Li, N., Locke, A. E., Verweij, N., et al. (2021) · Science · doi:10.1126/science.abe0348 · Cited by 33
Self-citationProduction of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
Yang, D., Zhang, J., Xu, J., Zhu, T., Fan, Y., Fan, J., & Chen, Y. E. (2013) · Journal of Visualized Experiments · doi:10.3791/50957 · Cited by 32
Morton, A. M., Furtado, J. D., Lee, J., Amerine, W., Davidson, M. H., & Sacks, F. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.005 · Cited by 33
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 37
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
Tietjen, I., Hovingh, G. K., Singaraja, R. R., Radomski, C., Barhdadi, A., McEwen, J., Chan, E., Mattice, M., Legendre, A., Franchini, P. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037437 · Cited by 33
“Mutations in both APOC3 and LPL also lead to large changes in HDLc [13,29,30], further”
BackgroundNagiec, M. M., Skepner, A. P., Negri, J. M., Eichhorn, M., Kuperwasser, N., Comer, E. J., Muncipinto, G., Subramanian, A., Clish, C. B., Musunuru, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120295 · Cited by 32
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury
Schunk, S. J., Hermann, J., Sarakpi, T., Triem, S., Lellig, M., Hahm, E., Zewinger, S., Schmit, D., Becker, E., Möllmann, J., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021040503 · Cited by 31
Cardiovascular pharmacogenomics: current status and future directions
Roden, D. M. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.78 · Cited by 36
Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib
Maitland, M. L., Xu, C., Cheng, Y., Kistner‐Griffin, E., Ryan, K. A., Karrison, T. G., Das, S., Torgerson, D. G., Gamazon, E. R., Thomeas, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1683 · Cited by 30
Self-citationGene silencing approaches for the management of dyslipidaemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.010 · Cited by 32
Metadata
- Authors
- Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., Mitchell, B. D., Miller, M., O'Connell, J. R., & Shuldiner, A. R.
- Affiliations
- University of Maryland, Baltimore (US)
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Corresponding author
- Pollin, Toni I.
- ORCID
- Venue
- Science
- Published
- 2008-12-12
- Volume
- 322
- Issue
- 5908
- Pages
- 1702-1705
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2673993
- OpenAlex
- W2061100095
- Semantic Scholar
- d46146fa9f89ec4722b99bade97f6a1d685409c0
- Cited by
- 688
- References
- 34
- Citations by year
- 2026: 31 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 30 · 2021: 41 · 2020: 38 · 2019: 36 · 2018: 52 · 2017: 51 · 2016: 54 · 2015: 49 · 2014: 55 · 2013: 43 · 2012: 23
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01-AG-18728, R01AG018728)
- National Heart, Lung, and Blood Institute (U01HL72515, U01HL084756, U01HL072515, R01HL088119)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR046838)
- National Center for Research Resources (M01RR016500, M01RR000052, M01RR 16500)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, plasma lipid profile, triglycerides, HDL cholesterol, LDL cholesterol, coronary artery calcification, subclinical atherosclerosis, cardioprotection, coronary artery disease, lipolysis
- MeSH terms
- Adult, Cholesterol, Christianity, Coronary Artery Disease, Dietary Fats, Fasting, Female, Haplotypes, Heterozygote, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mutation, Pedigree, Pennsylvania, Risk Factors, Triglycerides, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Apolipoprotein C-III, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.